P2X7 Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The P2X7 receptor is an ATP-gated ion channel that plays a critical role in immune signaling and neuroinflammation. It is unique among P2X receptors for its ability to form large pores that allow passage of molecules up to 900 Da when repeatedly activated. This makes it a key player in the innate immune response and a therapeutic target for neurodegenerative diseases. [1]
P2X7 is a purinergic receptor that responds to extracellular ATP and mediates fast calcium influx and inflammatory signaling. P2X7 activation triggers NLRP3 inflammasome assembly, cytokine release, and cell death. It is expressed in microglia and immune cells and is a therapeutic target for neuroinflammatory diseases. [2]
This protein is involved in: [3]
| Attribute | Value | [4]
|-----------|-------| [5]
| Protein Name | P2X7 Receptor | [6]
| Gene | P2RX7 |
| UniProt ID | Q99572 |
| PDB Structures | 5U1L, 6U9V, 7KB5 |
| Molecular Weight | 66 kDa (monomer) |
| Subcellular Localization | Plasma membrane, lipid rafts |
| Protein Family | P2X purinergic receptor family |
The P2X7 receptor is a trimeric ATP-gated ion channel with the following structural features:
The receptor exists as a homotrimer, and upon ATP binding, the channel opens to allow Na+ and Ca2+ influx. Repeated or prolonged stimulation leads to formation of the larger pore state.
P2X7 receptors mediate rapid ATP signaling in immune cells:
In the central nervous system, P2X7 is expressed on microglia, astrocytes, neurons, and oligodendrocyte progenitor cells.
P2X7 contributes to AD pathogenesis through:
In PD, P2X7:
P2X7 in ALS:
P2X7 signaling:
P2X7 activates multiple downstream pathways:
Key interacting proteins include:
P2X7 is a major drug target for neuroinflammation:
| Drug/Approach | Mechanism | Status | Clinical Trials |
|---|---|---|---|
| Brilacidin | P2X7 antagonist | Phase 2 | MS, inflammatory diseases |
| AZD9056 | P2X7 antagonist | Phase 2 | Rheumatoid arthritis |
| CE-224535 | P2X7 antagonist | Phase 2 | Rheumatoid arthritis |
| JNJ-47965567 | P2X7 antagonist | Phase 1 | Healthy volunteers |
| Brilliant Blue G | P2X7 antagonist | Preclinical | Neuroprotection |
| A-438079 | P2X7 antagonist | Preclinical | Anti-inflammatory |
BTK inhibitors (tolebrutinib, fenestrinib) indirectly modulate P2X7 signaling.
Current areas of investigation:
The study of P2X7 Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sperlágh B, et al. P2X7 receptors in CNS neurons: Key players in health and disease. 2017. ↩︎
Miras-Portugal MT, et al. P2X7 receptors in neurodegeneration. 2021. ↩︎
Liu HD, et al. P2X7 receptor: A potential therapeutic target in CNS disorders. 2020. ↩︎
Burnstock G. Purinergic signaling in neurodegenerative diseases. 2014. ↩︎
Andrejew R, et al. The P2X7 receptor as a therapeutic target in Parkinson's disease. 2020. ↩︎
Bartlett R, et al. P2X7 receptors in neurological disease. 2017. ↩︎